SNM (also known as sacral nerve stimulation) therapy is delivered by a stimulator implanted subcutaneously in the upper buttock. The stimulator generates electric pulses. Lead electrodes implanted through corresponding sacral foramen transmit these pulses from the stimulator to the sacral nerves.
Status In progress
Process MT
ID number 417

Provisional Schedule

Committee meeting: 1 24 January 2020
Draft guidance: 1 14 February 2020 - 13 March 2020
Committee meeting: 2 20 March 2020
Resolution 20 April 2020
Expected publication 01 June 2020

Project Team

Project lead Tosin Oladapo

Email enquiries


External assessment group Cedar
Manufacturers Axonics Modulation Technologies
Professional groups Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  British Society of Urogynaecology
  British Association of Urological Surgeons


Key events during the development of the guidance:

Date Update
20 August 2019 Scope published
10 July 2019 Stakeholder registration opens

For further information on how we develop guidance, please see our page about NICE medical technologies guidance